Derma Sciences, Inc. (NASDAQ:DSCI) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued on Tuesday.
According to Zacks, “Derma Sciences, Inc. is engaged in the development, marketing and sales of proprietary and non-proprietary topical, nutrient-based wound care products for the management of certain chronic, non-healing skin ulcerations such as pressure and venous ulcers, surgical incisions and burns. (PRESS RELEASE) “
Derma Sciences (NASDAQ:DSCI) remained flat at $5.00 during midday trading on Tuesday. The company had a trading volume of 46,547 shares. The stock’s market cap is $141.34 million. The stock’s 50-day moving average is $4.88 and its 200 day moving average is $4.66. Derma Sciences has a 52 week low of $2.85 and a 52 week high of $5.86.
Derma Sciences (NASDAQ:DSCI) last released its quarterly earnings results on Thursday, November 10th. The company reported ($0.05) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.04) by $0.01. Derma Sciences had a negative return on equity of 4.09% and a negative net margin of 12.32%. The company earned $21.80 million during the quarter, compared to the consensus estimate of $23.90 million. On average, equities research analysts predict that Derma Sciences will post ($0.12) earnings per share for the current year.
WARNING: “Derma Sciences, Inc. (DSCI) Upgraded to Hold by Zacks Investment Research” was first reported by BBNS and is owned by of BBNS. If you are accessing this story on another site, it was illegally stolen and reposted in violation of international trademark and copyright legislation. The correct version of this story can be accessed at https://baseballnewssource.com/markets/derma-sciences-inc-dsci-upgraded-to-hold-by-zacks-investment-research/342590.html.
Institutional investors have recently made changes to their positions in the stock. Emerald Acquisition Ltd. acquired a new position in shares of Derma Sciences during the second quarter worth $202,000. Connor Clark & Lunn Investment Management Ltd. increased its position in shares of Derma Sciences by 35.5% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 68,300 shares of the company’s stock worth $319,000 after buying an additional 17,900 shares in the last quarter. Baker BROS. Advisors LP acquired a new position in shares of Derma Sciences during the third quarter worth $17,524,000. The Manufacturers Life Insurance Company acquired a new position in shares of Derma Sciences during the third quarter worth $2,839,000. Finally, UBS Asset Management Americas Inc. increased its position in shares of Derma Sciences by 18.6% in the third quarter. UBS Asset Management Americas Inc. now owns 236,950 shares of the company’s stock worth $1,107,000 after buying an additional 37,134 shares in the last quarter. 59.12% of the stock is owned by institutional investors and hedge funds.
About Derma Sciences
Derma Sciences, Inc (Derma Sciences) is a medical device company. The Company operates through two segments: advanced wound care and traditional wound care products. Advanced wound care products principally consist of both novel and otherwise differentiated dressings, devices and skin substitutes designed to promote wound healing and/or prevent infection.
Receive News & Ratings for Derma Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Derma Sciences Inc. and related companies with our FREE daily email newsletter.